The E3 Ubiquitin Protein Ligase CBL B pipeline drugs market research report outlays comprehensive information on the E3 Ubiquitin Protein Ligase CBL B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the E3 Ubiquitin Protein Ligase CBL B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Unspecified Cancer. It also reviews key players involved in E3 Ubiquitin Protein Ligase CBL B targeted therapeutics development with respective active and dormant or discontinued products.
The E3 Ubiquitin Protein Ligase CBL B pipeline targets constitutes close to 15 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 7, and 5 respectively.
E3 Ubiquitin Protein Ligase CBL B overview
E3 ubiquitin-protein ligase CBL-B promotes proteosome-mediated protein degradation by transferring ubiquitin from an E2 ubiquitin-conjugating enzyme to a substrate. The encoded protein is involved in the regulation of immune response by limiting T-cell receptor, B-cell receptor, and high affinity immunoglobulin epsilon receptor activation.
For a complete picture of E3 Ubiquitin Protein Ligase CBL B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.